Showing results (1471-1480 of 1,686) with videos related to
Sort By:
Pageof 169
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 12, 2018
One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trialPatrick W Serruys, Rodrigo Modolo, Michael Reardon, et al.JACC. Cardiovascular Imaging|October 17, 2021
Prognostic Value of Computed Tomography-Derived Fractional Flow Reserve Comparison With Myocardial Perfusion ImagingAhmed Ibrahim Ahmed, Yushui Han, Mahmoud Al Rifai, et al.Journal of the American College of Cardiology|October 2, 2002
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT studyLaura S Fernandes, James E Tcheng, J Conor O'Shea, et al.Platelets|June 24, 2008
Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug developmentNeal S Kleiman, Jane E Freedman, Paula B Tracy, et al.The New England Journal of Medicine|October 31, 1996
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA InvestigatorsE M Ohman, P W Armstrong, R H Christenson, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 6, 2026
Prosthesis-patient mismatch with intra-annular self-expanding valves: an analysis of the PORTICO IDE trialGregory P Fontana, Ron Waksman, Arash Salemi, et al.Nature Communications|July 18, 2015
Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1Sabine Vettorazzi, Constantin Bode, Lien Dejager, et al.The American Journal of Cardiology|November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.American Heart Journal|April 25, 2007
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial diseasePaul Michael Grossman, Farrell Mendelsohn, Timothy D Henry, et al.Thrombosis and Haemostasis|September 7, 2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysOscar Ö Braun, Dominick J Angiolillo, Jose L Ferreiro, et al.Pageof 169